Stay up to date on the latest oncology and nursing conferences.
PARP Inhibitor Improves PFS in Pancreatic Cancer Subset
June 3rd 2019Maintenance therapy with olaparib (Lynparza) significantly improved progression-free survival (PFS) compared with placebo among patients with germline BRCA-mutated metastatic pancreatic cancer, according to results from the phase III POLO trial presented at the 2019 ASCO Annual Meeting.
Intervention, Education on Diabetes Necessary Among Breast Cancer Survivors
April 17th 2019Diabetes may be a risk factor for increased symptoms among breast cancer survivors, highlighting the need for interventions to control the disease, according to secondary analysis results presented at the ONS 44th Annual Congress.
Heated Chemo During Resection Shows No Benefit in Advanced CRC
July 13th 2018The addition of heated chemotherapy delivered to the abdomen during surgery delivered no survival benefit to patients with peritoneal carcinomatosis, according to phase III study results presented at the 2018 ASCO Annual Meeting.
Trial Induces 'Best Ever' Survival Data Among Young Patients with Certain T-Cell Cancers
July 10th 2018Adding nelarabine to escalating-dose methotrexate increased the 4-year disease-free survival rate to 91% in pediatric and young adult patients with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma, according to results from the phase III AALL0434 trial.